drugset / Trial / NCT02097641

Summary

This was a Phase 2a, randomized, double-blind, placebo-controlled, multi-center trial to assess the safety and efficacy of a single dose of Allogeneic Bone Marrow-derived Human Mesenchymal Stromal Cells (hMSCs) infusion in patients with Acute Respiratory Distress Syndrome (ARDS).

Timeline

Start
2014-03-15
Primary completion
2017-03-09
Completion
2018-02-09

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Allogeneic Bone Marrow-Derived Human Mesenchymal Stromal Cells Unknown 1e+07 cells/kg Intravenous